Zhou Dan, Li Yue, Tian Tian, Quan Wei, Wang Lei, Shao Qing, Fu Lian-Qiang, Zhang Xiao-Hong, Wang Xiao-Ye, Zhang Hui, Ma Yan-Min
Pharmazie. 2017 Aug 1;72(8):435-439. doi: 10.1691/ph.2017.7474.
Two types of cannabinoid (CB) receptors have been described in the human body: CB1 and CB2 receptors. CB1 receptor distribution may be related to the cannabinoid functions of memory and cognition regulation as well as motor control. In addition, the endocannabinoid system (ECS) related to CB1 receptors may be involved in human emotion regulation, especially depression occurrence. Indeed, CB1 receptors are all distributed in depression associated neuroanatomical structures and neural circuits. Both animal experiments and clinical studies have demonstrated that impairment of the ECS pathway is present in depression models and patients, and application of both CB1 receptor agonists and anandamide (cannabinoid-like substance) degradation inhibitors produce similar biochemical and behavioral effects as antidepressants. These findings provide a solid basis for understanding the ECS role in the formation and development of depression. Therefore, it can be inferred that the ECS may have an important function in both depression treatment and the effects of antidepressants.
人体中已发现两种类型的大麻素（CB）受体：CB1和CB2受体。CB1受体的分布可能与大麻素在记忆、认知调节以及运动控制方面的功能有关。此外，与CB1受体相关的内源性大麻素系统（ECS）可能参与人类情绪调节，尤其是抑郁症的发生。事实上，CB1受体分布于所有与抑郁症相关的神经解剖结构和神经回路中。动物实验和临床研究均表明，抑郁症模型和患者体内存在ECS通路受损的情况，应用CB1受体激动剂和花生四烯乙醇胺（类大麻素物质）降解抑制剂会产生与抗抑郁药相似的生化和行为效应。这些发现为理解ECS在抑郁症形成和发展中的作用提供了坚实基础。因此，可以推断ECS在抑郁症治疗及抗抑郁药疗效方面可能具有重要作用。
